Oxidized Low-Density Lipoprotein Suppresses Expression of Prostaglandin E Receptor Subtype EP3 in Human THP-1 Macrophages

EP3, one of four prostaglandin E2 (PGE2) receptors, is significantly lower in atherosclerotic plaques than in normal arteries and is localized predominantly in macrophages of the plaque shoulder region. However, mechanisms behind this EP3 expression pattern are still unknown. We investigated the underlying mechanism of EP3 expression in phorbol 12-myristate 13-acetate (PMA)-differentiated THP-1 macrophages with oxidized low-density lipoprotein (oxLDL) treatment. We found that oxLDL decreased EP3 expression, in a dose-dependent manner, at both the mRNA and protein levels. Moreover, oxLDL inhibited nuclear factor-kappa B (NF-kappa B)-dependent transcription of the EP3 gene by the activation of peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Finally, chromatin immunoprecipitation revealed decreased binding of NF-kappa B to the EP3 promoter with oxLDL and PPAR-gamma agonist treatment. Our results show that oxLDL suppresses EP3 expression by activation of PPAR-gamma and subsequent inhibition of NF-kappa B in macrophages. These results suggest that down-regulation of EP3 expression by oxLDL is associated with impairment of EP3-mediated anti-inflammatory effects, and that EP3 receptor activity may exert a beneficial effect on atherosclerosis.